{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:09:44Z","timestamp":1792404584054,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The relevance of repetitive [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD scintigraphy in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) remains unclear. We investigated the impact of tafamidis on cardiac [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD uptake, clinical, and laboratory markers at 6 and 12\u00a0months, and correlated 12\u00a0months [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD uptake regression with survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This single-center study enrolled 39 ATTRwt-CM patients. Upon treatment initiation with tafamidis, patients underwent follow-up [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD scintigraphy, and clinical and laboratory evaluations at 6\u00a0months (<jats:italic>n<\/jats:italic>\u2009=\u20096) and 12\u00a0months (<jats:italic>n<\/jats:italic>\u2009=\u200913), or both (<jats:italic>n<\/jats:italic>\u2009=\u200920).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Tafamidis resulted in a significant decline in Perugini score (6\u00a0months <jats:italic>p<\/jats:italic>\u2009=\u20090.008, 12\u00a0months <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and (semi-)quantitative [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD uptake (total cardiac uptake: baseline 816 [522\u2013933]\u00a0cps, vs. 6\u00a0months 634 [502\u2013734]\u00a0cps, <jats:italic>p<\/jats:italic>\u2009=\u20090.003, vs. 12\u00a0months 523 [108\u2013754]\u00a0cps, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Clinical and laboratory improvements were observed (NYHA: 6\u00a0months <jats:italic>p<\/jats:italic>\u2009=\u20090.007, 12\u00a0months <jats:italic>p<\/jats:italic>\u2009=\u20090.033; NT-proBNP: baseline 2586 [1271\u20135561]\u00a0ng\/L, vs. 6\u00a0months 2526 [1109\u20134786]\u00a0ng\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.016, vs. 12\u00a0months 2340 [1411\u20134749]\u00a0ng\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.012). In Kaplan\u2013Meier analysis, a decrease in right ventricular [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD tracer uptake equal to or greater than the median value at 12\u00a0months (-30%) was associated with improved survival (log-rank <jats:italic>p<\/jats:italic>\u2009=\u20090.021).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Tafamidis in ATTRwt-CM resulted in significant reductions of cardiac [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD uptake, NYHA class, and cardiac biomarkers at 6 and 12\u00a0months. Regression of right ventricular [<jats:sup>99m<\/jats:sup>Tc]Tc-DPD uptake at 12\u00a0months was associated with improved survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07092-7","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:44:06Z","timestamp":1738809846000},"page":"2529-2537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2098-9772","authenticated-orcid":false,"given":"Maria","family":"Ungericht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Messner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Puelacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Staggl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Michael","family":"Zaruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Stephan","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Poelzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"7092_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","volume":"71","author":"J Rubin","year":"2020","unstructured":"Rubin J, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020;71:203\u201319. https:\/\/doi.org\/10.1146\/annurev-med-052918-020140.","journal-title":"Annu Rev Med"},{"key":"7092_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"key":"7092_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23:277\u201385. https:\/\/doi.org\/10.1002\/ejhf.2027.","journal-title":"Eur J Heart Fail"},{"key":"7092_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"7092_CR5","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/cir.0000000000001063.","journal-title":"Circulation"},{"key":"7092_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","volume":"30","author":"R Rettl","year":"2023","unstructured":"Rettl R, Duca F, Binder C, Dachs TM, Cherouny B, Camuz Ligios L, et al. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy. Amyloid. 2023;30:127\u201337. https:\/\/doi.org\/10.1080\/13506129.2022.2131385.","journal-title":"Amyloid"},{"key":"7092_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","volume":"23","author":"R Rettl","year":"2022","unstructured":"Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:767\u201380. https:\/\/doi.org\/10.1093\/ehjci\/jeab226.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7092_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-023-10380-9","author":"D Wu","year":"2024","unstructured":"Wu D, Chen W. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy. Heart Fail Rev. 2024. https:\/\/doi.org\/10.1007\/s10741-023-10380-9.","journal-title":"Heart Fail Rev"},{"key":"7092_CR9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133:2404\u201312. https:\/\/doi.org\/10.1161\/circulationaha.116.021612.","journal-title":"Circulation"},{"key":"7092_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s12350-019-01893-8","volume":"27","author":"F Caobelli","year":"2020","unstructured":"Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative (99m)Tc-DPD SPECT\/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27:1456\u201363. https:\/\/doi.org\/10.1007\/s12350-019-01893-8.","journal-title":"J Nucl Cardiol"},{"key":"7092_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26:158\u201373. https:\/\/doi.org\/10.1007\/s12350-018-01552-4.","journal-title":"J Nucl Cardiol"},{"key":"7092_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","volume":"25","author":"JC Ross","year":"2018","unstructured":"Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, et al. Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid. 2018;25:203\u201310. https:\/\/doi.org\/10.1080\/13506129.2018.1520087.","journal-title":"Amyloid"},{"key":"7092_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jcmg.2014.03.002","volume":"7","author":"AV Kristen","year":"2014","unstructured":"Kristen AV, Scherer K, Buss S, Siepen F, Haufe S, Bauer R, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:502\u201310. https:\/\/doi.org\/10.1016\/j.jcmg.2014.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7092_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016;1:880\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2016.2839.","journal-title":"JAMA Cardiol"},{"key":"7092_CR15","doi-asserted-by":"publisher","unstructured":"Ungericht M, Groaz V, Messner M, Schuetz T, Brunelli L, Zaruba MM, et al. Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis. Amyloid. 2023;1\u201310. https:\/\/doi.org\/10.1080\/13506129.2023.2239986.","DOI":"10.1080\/13506129.2023.2239986"},{"key":"7092_CR16","doi-asserted-by":"publisher","first-page":"e024717","DOI":"10.1161\/jaha.121.024717","volume":"11","author":"M Morioka","year":"2022","unstructured":"Morioka M, Takashio S, Nakashima N, Nishi M, Fujiyama A, Hirakawa K, et al. Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild-Type Transthyretin Amyloid Cardiomyopathy. J Am Heart Assoc. 2022;11:e024717. https:\/\/doi.org\/10.1161\/jaha.121.024717.","journal-title":"J Am Heart Assoc"},{"key":"7092_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","volume":"24","author":"R Rettl","year":"2023","unstructured":"Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, et al. Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019\u201330. https:\/\/doi.org\/10.1093\/ehjci\/jead030.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7092_CR18","doi-asserted-by":"publisher","unstructured":"Rettl R, Calabretta R, Duca F, Binder C, Kronberger C, Willixhofer R, et al. Reduction in (99m)Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid. 2023;1\u201310. https:\/\/doi.org\/10.1080\/13506129.2023.2247136.","DOI":"10.1080\/13506129.2023.2247136"},{"key":"7092_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","volume":"64","author":"M Papathanasiou","year":"2023","unstructured":"Papathanasiou M, Kessler L, Bengel FM, Jakstaite AM, Kersting D, Varasteh Z, et al. Regression of Myocardial (99m)Tc-DPD Uptake After Tafamidis Treatment of Cardiac Transthyretin Amyloidosis. J Nucl Med. 2023;64:1083\u20136. https:\/\/doi.org\/10.2967\/jnumed.122.265352.","journal-title":"J Nucl Med"},{"key":"7092_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073.","journal-title":"J Am Coll Cardiol"},{"key":"7092_CR21","doi-asserted-by":"publisher","first-page":"e030512","DOI":"10.1161\/jaha.123.030512","volume":"13","author":"AL Yu","year":"2024","unstructured":"Yu AL, Chen YC, Tsai CH, Wu YA, Su MY, Chou CH, et al. Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography\/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy. J Am Heart Assoc. 2024;13:e030512. https:\/\/doi.org\/10.1161\/jaha.123.030512.","journal-title":"J Am Heart Assoc"},{"key":"7092_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","volume":"13","author":"PR Scully","year":"2020","unstructured":"Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker. JACC Cardiovasc Imaging. 2020;13:1353\u201363. https:\/\/doi.org\/10.1016\/j.jcmg.2020.03.020.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7092_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.066524","author":"A Porcari","year":"2024","unstructured":"Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al. Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy. Circulation. 2024. https:\/\/doi.org\/10.1161\/circulationaha.123.066524.","journal-title":"Circulation"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07092-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:17:42Z","timestamp":1748427462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07092-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7092"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07092-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted at the Medical University of Innsbruck following the Declaration of Helsinki and was approved by the local ethical committee. Written informed consent was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors consent to publish and print the data contained in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Maria Ungericht and Thomas Schuetz received lecture fees from Pfizer outside the submitted work. Moritz Messner received research grants from the state of Tyrol\u00a0outside the submitted work. Christian Puelacher received grants from the Swiss Heart Foundation, the University Hospital Basel, and Roche Diagnostics outside the submitted work. Gerhard Poelzl received speaker honoraria from Pfizer, Alnylam and Astra Zeneca outside the submitted work. All other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}